Toxicity and costs of cancer treatment reduced by deferring CDK4/6 inhibitor use
Year: 2024
Type: article
Abstract: The SONIA study shows that early use of inhibitors that target both CDK4 and CDK6 (hereafter, CDK4/6) in metastatic breast cancer prolongs time on treatment but does not improve patient outcomes. Postponing innovative treatments to a later stage of the disease could thus safely reduce the time on treatment, the number of adverse effects for people with breast cancer and the burden on health-care resources. No difference in survival outcomes between use of CDK4/6 inhibitors as first- or second-line treatment in metastatic breast cancer.
Source: Nature
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $12,290
OpenAlex ID: W4404755698